Goldman Sachs analyst Salveen Richter downgraded Taysha Gene Therapies to Neutral from Buy with a price target of $3, down from $16. The analyst is constructive on Astellas Pharma’s recent strategic investment but is taking a "more measured outlook" on Taysha’s portfolio on the back of its reprioritization of assets and into regulatory updates.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TSHA:
- Taysha Gene Therapies price target lowered to $19 from $22 at Guggenheim
- Taysha Gene Therapies price target lowered to $16 from $18 at Needham
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Taysha Gene Therapies initiated with a Buy at Canaccord
- Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
